World's First: Juvensis Therapeutics' Homegrown Telomere-Targeted Gene Therapy for Heart Failure Granted FDA IND Approval for U.S. Clinical Studies

JV101 Injection, Juvensis Therapeutics' independently developed core product, recently received Investigational New Drug (IND) approval from the U.S. Food and Drug Administration (FDA) for clinical trials, planning to conduct a Phase I study for idiopathic dilated cardiomyopathy (IDCM) in the United States.

This is the world's first telomere-targeted gene therapy for heart failure to receive FDA clinical approval. Notably, the IND application received no major deficiencies or clinical holds during the FDA's 30-day standard review period, allowing the study to commence directly upon approval. VCBeat has learned.

Heart failure is a major global public health challenge. Epidemiological data show that there are over 64.3 million heart failure patients worldwide. In China, the disease burden is even more pronounced. The Report on Progress in Prevention and Treatment of Heart Failure in China (White Paper), released in April 2026, shows that by 2023, the number of heart failure patients in China had reached approximately 14.3 million, with about 3 million new cases annually. This condition is characterized by high incidence, high mortality, high hospitalization rates, low quality of life, and a substantial economic burden.

Despite the continuous improvement in diagnosis and treatment standards in recent years, the long-term prognosis for heart failure patients remains poor. According to the data from the aforementioned white paper, the all-cause mortality rate among heart failure patients was 13.7% at one year post-discharge, rising to 28.2% at three years, with frequent hospital readmissions. This means that for a large number of patients, heart failure remains a progressive disease that is difficult to reverse and requires long-term management.

Over the past few decades, heart failure treatment has continuously evolved. Standard therapies represented by angiotensin-converting enzyme inhibitors (ACEIs), beta-blockers, and diuretics have laid the foundation for modern heart failure management. In recent years, novel agents such as angiotensin receptor-neprilysin inhibitors (ARNIs), sodium-glucose cotransporter 2 (SGLT2) inhibitors, and soluble guanylate cyclase (sGC) stimulators have been incorporated into the therapeutic armamentarium, further reducing mortality and rehospitalization risks.

However, the core rationale of these therapies remains to delay disease progression by modulating the neuroendocrine system and reducing cardiac workload. For established myocardial injury, pathological remodeling, and fibrosis, clinical treatments that directly target the upstream pathological mechanisms remain lacking. Particularly for patients with refractory heart failure, such as those with idiopathic dilated cardiomyopathy, definitive therapeutic options remain limited.

In this context, gene therapy is regarded as a potential breakthrough approach. However, due to the demanding requirements for cardiac delivery efficiency, the complexity of safety control, and the long validation cycle for long-term benefits, cardiovascular gene therapy is widely recognized as one of the most challenging areas within the field of gene therapy. As a result, few innovative projects have truly progressed to the stage of international clinical validation.

Unlike traditional drugs that modulate the neuroendocrine system, the newly approved JV101 targets a more upstream pathogenic mechanism: imbalance in telomere homeostasis.

Telomeres are located at the ends of chromosomes and play a crucial role in maintaining the stability of genetic material. With aging, oxidative stress, and accumulated damage, telomeres may shorten or become "uncapped," activating the DNA damage response (DDR) and inducing cellular senescence and dysfunction.

During the progression of heart failure, this process further activates the p53 signaling pathway, inhibiting the expression of peroxisome proliferator-activated receptor gamma coactivator-1α (PGC-1α) and mitochondrial transcription factor A (TFAM), leading to impaired mitochondrial function and metabolic imbalance, and ultimately driving pathological cardiac remodeling and fibrosis.

JV101 is designed based on the aforementioned mechanism, utilizing an adeno-associated virus serotype 9 (AAV9) vector to deliver catalytically inactivated human telomerase reverse transcriptase with preserved nuclear localization capability (modhTERT/CI-TERT).

This modified telomerase binds to damaged telomeric DNA in a TPP1-dependent manner, achieving "telomere recapping protection," inhibiting the ataxia-telangiectasia mutated (ATM)–p53-mediated DNA damage response (DDR), restoring the expression of PGC-1α and TFAM, repairing mitochondrial ultrastructure, and increasing mitochondrial DNA copy number, thereby improving energy metabolism in cardiomyocytes.

This design also constitutes several features that distinguish JV101 from existing therapies.

First, its innovation is reflected in its mechanism of action. JV101 targets the upstream pathological mechanism of telomere damage, becoming the world's first telomere-targeted gene therapy for heart failure to receive FDA IND approval.

Secondly, in terms of delivery strategy, JV101 utilizes an AAV9 vector combined with a cardiac troponin T (cTnT) promoter design, thereby achieving specific expression of the therapeutic gene in cardiomyocytes to enhance targeting efficiency and reduce potential off-target risks.

Furthermore, based on the animal study results disclosed by the company, a single intracoronary administration of JV101 demonstrated therapeutic efficacy lasting more than 12 months, suggesting its potential for long-term effects. However, whether this long-term benefit can be validated in larger-scale clinical studies remains to be further supported by subsequent data.

In fact, behind JV101's pioneering entry into the international clinical validation phase lies an original technology translation pathway centered on the continuous advancement of telomere biology.

Founded in 2021, Juvensis Therapeutics focuses on cardiovascular gene therapy. Centered on the scientific hypothesis of "restoring telomere homeostasis," the company has progressively established a comprehensive R&D system encompassing disease mechanism research, target discovery, vector design, and clinical translation, while building two core technology platforms: precise telomere regulation and cardiomyocyte-targeted delivery.

The company's core founding team is led by Professor Zhang Jiayu from Shanghai Ninth People's Hospital, Shanghai Jiao Tong University School of Medicine, and the Shanghai Institute for Precision Medicine. The team has long been engaged in research on telomere biology and cardiovascular aging, with related findings published in international journals such as eBioMedicine and Cardiovascular Research.

In April 2026, the team further elucidated the molecular mechanism by which JV101 improves heart failure through telomere re-protection-mediated regulation of pathological telomere–mitochondrial DNA communication, providing mechanistic support for subsequent clinical development of the product.

The FDA's approval of this IND is based on existing exploratory human studies and multiple lines of nonclinical evidence. Relevant data were presented at the 2026 Annual Meeting of the American Society of Gene & Cell Therapy (ASGCT).

The first-in-human exploratory study conducted in patients with heart failure caused by dilated cardiomyopathy has provided a crucial basis for JV101 to enter the international clinical stage.

From a safety perspective, no dose-limiting toxicities (DLTs) were reported in subjects receiving either the low or high dose within 28 days post-dose, and the maximum tolerated dose (MTD) was not reached. Throughout the entire follow-up period, no JV101-related serious adverse events were observed, nor were any clear safety risks attributed to immunogenicity identified, indicating overall good tolerability.

In terms of preliminary efficacy, patients in both dose groups exhibited a sustained increase in left ventricular ejection fraction (LVEF), along with a decrease in left ventricular end-diastolic volume (LVEDV). Meanwhile, right ventricular function improved, and N-terminal pro-B-type natriuretic peptide (NT-proBNP) levels trended downward overall.

In addition to human data, the research team conducted a systematic evaluation of JV101 in multiple disease models.

Seven nonclinical studies concurrently presented at the ASGCT covered pressure overload-induced heart failure, post-myocardial infarction heart failure, diabetic cardiomyopathy, hypertrophic cardiomyopathy (HCM), heart failure with preserved ejection fraction (HFpEF), cardiorenal syndrome type 4 (CRS4), and human induced pluripotent stem cell-derived cardiomyocytes (hiPSC-CMs) models.

Current results indicate that JV101 demonstrates the potential to improve cardiac function and alleviate pathological damage across various models. For instance, in a post-myocardial infarction heart failure model, it reduced myocardial fibrosis and decreased scar area; in a diabetic cardiomyopathy model, it ameliorated abnormalities in myocardial energy metabolism; and in a heart failure with preserved ejection fraction (HFpEF) model, it restored diastolic function. Furthermore, studies in a cardiorenal syndrome type 4 (CRS4) model suggest that while improving cardiac function, JV101 may also exert certain beneficial effects on renal function.

These results suggest that intervention strategies targeting the upstream mechanism of telomere homeostasis imbalance may not be limited to a specific type of heart failure, but rather have potential for broader disease coverage.

Overall, from the first-in-human exploratory study to nonclinical validation covering multiple heart failure subtypes, JV101 has established a continuous chain of evidence spanning preclinical to early clinical stages. However, whether this can translate into long-term, stable clinical benefits still requires further validation through subsequent international multicenter clinical trials.

From a longer-term perspective, the significance of JV101 receiving FDA IND approval may extend beyond simply enabling a product to enter U.S. clinical trials.

In recent years, the frontiers of gene therapy exploration have gradually expanded from rare genetic disorders to chronic diseases with larger patient populations.

Currently, globally approved gene therapy products remain predominantly focused on hereditary eye diseases, hematologic disorders, and neurological or neuromuscular diseases, with most targeting indications with relatively limited patient populations. In contrast, due to greater challenges in delivery efficiency, safety control, and long-term benefit validation, the number of gene therapy products in the cardiovascular field that have entered clinical stages remains relatively limited.

In this context, the FDA's approval of the IND application for JV101 signifies that a novel therapeutic approach has entered the global validation system. For telomere regulation, a field previously confined largely to basic research, the FDA's authorization to initiate clinical trials indicates that its mechanistic rationale, nonclinical evidence, and clinical development plan have received preliminary recognition from international regulatory authorities.

From a longer-term perspective, this exploration is not simply about adding one more treatment option, but rather urges the industry to shift its focus to the upstream stages of disease onset and progression, seeking novel intervention strategies that diverge from traditional long-term pharmacological management. Whether telomere regulation can ultimately be translated into stable and durable clinical benefits remains to be answered by subsequent international multicenter studies.

At the very least, this therapeutic approach, which has long remained in the stage of basic research, has now reached the threshold of FDA clinical trials. For heart failure patients who have long been limited to "delayed treatment," the future may offer options beyond long-term pharmacological management alone.